Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 9, 2019
Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysisRong He, Daniel J Devine, Zheng Jin Tu, et al.
The American Journal of Surgical Pathology|June 14, 2013
Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiationDava S West, Ahmet Dogan, Patrick S Quint, et al.
Leukemia & Lymphoma|October 3, 2018
Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patientsKevin C Miller, Aref Al-Kali, Mithun V Shah, et al.
The American Journal of Surgical Pathology|May 16, 2018
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal RelatednessRong He, Wei Ding, David S Viswanatha, et al.
The Journal of Molecular Diagnostics : JMD|July 10, 2026
Performance Evaluation of a Custom Myeloid Assay on the Genexus Integrated Sequencer from a Wide Spectrum of Clinical VariantsMichelle A Dina, Joseph H Blommel, Jagadheshwar Balan, et al.
Seminars in Arthritis and Rheumatism|July 25, 2025
Developing efficient predictive models for the diagnosis of VEXAS syndromeDaniel Montes, Andrew C Hanson, Hannah E Langenfeld, et al.
British Journal of Haematology|May 5, 2023
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasmsMark Gurney, Ismahene Chekkaf, Anmol Baranwal, et al.
American Journal of Clinical Pathology|May 12, 2021
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 MutationsElise R Venable, Dong Chen, Constance P Chen, et al.
American Journal of Hematology|April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsClive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
Blood Advances|December 6, 2021
A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemiaStanley W K Ng, Tracy Murphy, Ian King, et al.
Pageof 8